Payment overview · 2025
General Payments
$3,083.54
82 reported records · 17 companies
Healthcare provider profile · identity verified
Mark A Rasak, DO
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · LIVONIA, MI · NPI 1053391920
Verified facts
What the public records show
CMS Open Payments records show Mark A Rasak, DO received $3,083.54 in general payments during 2025 across 82 reported records.
Lantheus Medical Imaging, Inc. accounted for 45.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brilinta, Creon, Eliquis, Jardiance, Linzess, Opsumit, Trelegy Ellipta, Verquvo, Wegovy, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Opsumit by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 464 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Trelegy Ellipta by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 464 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYNDAMAX as an associated drug or biological on 1880 records involving 1527 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vyndamax by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lantheus Medical Imaging, Inc. | Unresolved — no canonical attribution shown | $1,386.90 | 45.0% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $319.69 | 10.4% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $272.27 | 8.8% | 13 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $210.42 | 6.8% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $142.15 | 4.6% | 8 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $137.03 | 4.4% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $136.05 | 4.4% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $121.39 | 3.9% | 6 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $71.70 | 2.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.76 | 1.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $54.04 | 1.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.60 | 1.6% | 3 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $43.77 | 1.4% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $32.47 | 1.1% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $17.22 | 0.6% | 1 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $16.25 | 0.5% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.83 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,696.64 | 80 |
| Debt forgiveness | $1,386.90 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DEFINITY Normalized: definity |
Drug | Lantheus Medical Imaging, Inc. | $1,386.90 | 2 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $319.69 | 10 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $210.42 | 12 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $195.85 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $136.05 | 6 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $121.74 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $121.39 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $113.55 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $95.28 | 5 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $71.70 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $62.16 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $56.76 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $56.76 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $49.60 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.87 | 3 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $43.77 | 2 | 2025 |
Source payment records
|
|||||
| BRILINTA Normalized: brilinta |
Drug | AstraZeneca Pharmaceuticals LP | $41.11 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.95 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $32.47 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $32.47 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRILINTA brilinta |
2025 | Brilinta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 464 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 141 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OPSUMIT opsumit |
2025 | Opsumit | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 101 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
115 | 24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
141 | 33 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
464 | 115 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
101 | 30 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
156 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
142 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
68 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
464 | 115 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | VYNDAMAX open payments reported associated product |
CMS Open Payments — General Payments 1880 supporting records · 1527 recipient NPIs · example record 1228795749 |
Vyndamax · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1062 | 287 |
| Amlodipine Besylate | Amlodipine Besylate | 759 | 215 |
| Xarelto | Rivaroxaban | 665 | 162 |
| Metoprolol Succinate | Metoprolol Succinate | 641 | 177 |
| Clopidogrel | Clopidogrel Bisulfate | 511 | 136 |
| Eliquis | Apixaban | 464 | 115 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 456 | 139 |
| Carvedilol | Carvedilol | 441 | 116 |
| Losartan Potassium | Losartan Potassium | 407 | 120 |
| Pantoprazole Sodium | Pantoprazole Sodium | 398 | 125 |
| Ezetimibe | Ezetimibe | 386 | 118 |
| Alprazolam | Alprazolam | 365 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 358 | 109 |
| Lisinopril | Lisinopril | 335 | 96 |
| Omeprazole | Omeprazole | 311 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 304 | 91 |
| Potassium Chloride | Potassium Chloride | 300 | 91 |
| Metformin Hcl | Metformin Hcl | 296 | 88 |
| Furosemide | Furosemide | 290 | 92 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 285 | 85 |
| Simvastatin | Simvastatin | 263 | 73 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 240 | 54 |
| Atenolol | Atenolol | 229 | 56 |
| Famotidine | Famotidine | 223 | 67 |
| Gabapentin | Gabapentin | 217 | 58 |
| Doxazosin Mesylate | Doxazosin Mesylate | 189 | 50 |
| Spironolactone | Spironolactone | 166 | 53 |
| Entresto | Sacubitril/Valsartan | 156 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 152 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 149 | 63 |
| Tramadol Hcl | Tramadol Hcl | 149 | 50 |
| Digoxin | Digoxin | 143 | 45 |
| Ozempic | Semaglutide | 142 | 29 |
| Jardiance | Empagliflozin | 141 | 33 |
| Donepezil Hcl | Donepezil Hcl | 140 | 39 |
| Ranolazine Er | Ranolazine | 125 | 25 |
| Azithromycin | Azithromycin | 122 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 120 | 36 |
| Farxiga | Dapagliflozin Propanediol | 115 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 103 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 101 | 30 |
| Warfarin Sodium | Warfarin Sodium | 101 | 27 |
| Methylprednisolone | Methylprednisolone | 95 | 68 |
| Allopurinol | Allopurinol | 91 | 26 |
| Levofloxacin | Levofloxacin | 87 | 66 |
| Amiodarone Hcl | Amiodarone Hcl | 82 | 26 |
| Januvia | Sitagliptin Phosphate | 81 | 16 |
| Ramipril | Ramipril | 77 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 76 | 25 |
| Montelukast Sodium | Montelukast Sodium | 76 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 20 |
| Nitroglycerin | Nitroglycerin | 73 | 31 |
| Fenofibrate | Fenofibrate | 70 | 17 |
| Valsartan | Valsartan | 70 | 20 |
| Vascepa | Icosapent Ethyl | 70 | 14 |
| Clonazepam | Clonazepam | 68 | 11 |
| Rybelsus | Semaglutide | 68 | 12 |
| Midodrine Hcl | Midodrine Hcl | 67 | 18 |
| Icosapent Ethyl | Icosapent Ethyl | 65 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 65 | 21 |
| Bumetanide | Bumetanide | 62 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 20 |
| Metformin Hcl Er | Metformin Hcl | 59 | 19 |
| Trazodone Hcl | Trazodone Hcl | 58 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 14 |
| Lorazepam | Lorazepam | 52 | suppressed |
| Finasteride | Finasteride | 50 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | suppressed |
| Ibuprofen | Ibuprofen | 47 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 13 |
| Memantine Hcl | Memantine Hcl | 44 | 16 |
| Sertraline Hcl | Sertraline Hcl | 43 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 42 | 11 |
| Benazepril Hcl | Benazepril Hcl | 42 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 42 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | 13 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 38 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | 13 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 37 | suppressed |
| Glipizide | Glipizide | 37 | 12 |
| Klor-Con M20 | Potassium Chloride | 37 | 14 |
| Meloxicam | Meloxicam | 37 | suppressed |
| Nifedipine Er | Nifedipine | 37 | 12 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 36 | 12 |
| Candesartan Cilexetil | Candesartan Cilexetil | 36 | suppressed |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 23 |
| Nebivolol Hcl | Nebivolol Hcl | 35 | 11 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 34 | 12 |
| Varenicline Tartrate | Varenicline Tartrate | 34 | suppressed |
| Verapamil Er | Verapamil Hcl | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 20 |
| Lactulose | Lactulose | 33 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Sotalol | Sotalol Hcl | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Mirtazapine | Mirtazapine | 31 | 12 |
| Prednisone | Prednisone | 31 | 16 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Baclofen | Baclofen | 29 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 15 |
| Propafenone Hcl Er | Propafenone Hcl | 29 | suppressed |
| Brilinta | Ticagrelor | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | suppressed |
| Creon | Lipase/Protease/Amylase | 26 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Metolazone | Metolazone | 26 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 15 |
| Diazepam | Diazepam | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | 11 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Verquvo | Vericiguat | 22 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Glyburide | Glyburide | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Pancreaze | Lipase/Protease/Amylase | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Wegovy | Semaglutide | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Tadalafil | Tadalafil | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Isradipine | Isradipine | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Vyndamax | Tafamidis | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Opsumit | Macitentan | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,083.54 · 82 records | Lantheus Medical Imaging, Inc. | AMVUTTRA, Attruby, BREZTRI, BRILINTA, CAMZYOS, CAPVAXIVE, CREON, DEFINITY, ELIQUIS, EVKEEZA, FUROSCIX, JARDIANCE, LEQVIO, LINZESS, NURTEC ODT, OPSUMIT, SHINGRIX, TRELEGY ELLIPTA, Tyvaso, UPTRAVI, VERQUVO, VYNDAQEL, WAINUA, Wegovy, ZENPEP | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brilinta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error